S&P Futures
4,133.25 -14.50 (-0.35%) Dow Futures
33,880.00 -82.00 (-0.24%) Nasdaq Futures
12,570.50 -53.50 (-0.42%) Russell 2000 Futures
1,984.60 -8.90 (-0.45%) Crude Oil
73.55 +0.16 (+0.22%) Gold
1,889.70 +13.10 (+0.70%)
Corvus Pharmaceuticals, Inc. (CRVS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8523 |
| Open | 0.8687 |
| Bid | 0.8411 x 900 |
| Ask | 0.8688 x 800 |
| Day's Range | 0.8202 - 0.8687 |
| 52 Week Range | 0.6950 - 2.1700 |
| Volume | |
| Avg. Volume | 135,950 |
| Market Cap | 40.222M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8910 |
| Earnings Date | Mar 08, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRVS
Related Research
- Corvus Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 05/06/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- Simply Wall St.
Quite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholders
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
- GlobeNewswire
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE N
- GlobeNewswire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, along with an update
